Market Research Logo

Bronchitis - Pipeline Review, H2 2016

Bronchitis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Bronchitis - Pipeline Review, H2 2016’, provides an overview of the Bronchitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bronchitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Bronchitis
    • The report reviews pipeline therapeutics for Bronchitis by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Bronchitis therapeutics and enlists all their major and minor projects
    • The report assesses Bronchitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Bronchitis
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Bronchitis
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Bronchitis pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Bronchitis Overview
    Therapeutics Development
    Pipeline Products for Bronchitis - Overview
    Bronchitis - Therapeutics under Development by Companies
    Bronchitis - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Bronchitis - Products under Development by Companies
    Bronchitis - Companies Involved in Therapeutics Development
    AstraZeneca Plc
    DBV Technologies S.A.
    F. Hoffmann-La Roche Ltd.
    Hyundai Pharmaceutical Co., Ltd.
    Invion Limited
    Kyorin Pharmaceutical Co., Ltd.
    Mucosis B.V.
    Orbis Biosciences Inc
    Recipharm AB
    Bronchitis - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    alteplase - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZD-9668 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    erdosteine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HOB-051 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    KRPAM-1977X - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nadolol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nitric oxide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    prednisone - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    respiratory syncytial virus vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SynGEM - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Bronchitis - Dormant Projects
    Bronchitis - Discontinued Products
    Bronchitis - Product Development Milestones
    Featured News & Press Releases
    Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical
    Nov 10, 2015: Recipharm secures €25 million contract for Erdosteine API with Daewoong Pharmaceutical
    Oct 07, 2015: EVP R&D Dr Mitchell Glass discusses with BRR media data from the Phase 2 clinical trial of INV102 (nadolol) in Smoking Cessation
    Jun 23, 2015: Jubilant Life Sciences receives ANDA approval for Levofloxacin Tablets
    Apr 21, 2015: Advanced Inhalation Therapies to Present AIT-RSV Clinical Data at Two Upcoming Medical Meetings
    Jan 23, 2014: AIT To Present Phase II Clinical Data for NOxCureBR, A Treatment for Acute Bronchiolitis and RSV in Infants
    Jul 22, 2013: INVION ANNOUNCES COMMENCEMENT OF PHASE II CHRONIC BRONCHITIS CLINICAL TRIAL
    Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Bronchitis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Bronchitis - Pipeline by AstraZeneca Plc, H2 2016
    Bronchitis - Pipeline by DBV Technologies S.A., H2 2016
    Bronchitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
    Bronchitis - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016
    Bronchitis - Pipeline by Invion Limited, H2 2016
    Bronchitis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016
    Bronchitis - Pipeline by Mucosis B.V., H2 2016
    Bronchitis - Pipeline by Orbis Biosciences Inc, H2 2016
    Bronchitis - Pipeline by Recipharm AB, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Bronchitis - Dormant Projects, H2 2016
    Bronchitis - Dormant Projects (Contd..1), H2 2016
    Bronchitis - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Bronchitis, H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Targets, H2 2016
    Number of Products by Stage and Targets, H2 2016
    Number of Products by Mechanism of Actions, H2 2016
    Number of Products by Stage and Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report